What is Baze Labs?
Founded in 2014 by Philipp Schulte and Dr. Isam Haddad, Baze Labs operates at the intersection of biotechnology and consumer health. The company provides a sophisticated, blood-based at-home testing platform that bridges the gap between diagnostic insights and actionable wellness. By measuring micronutrient levels, Baze Labs delivers a closed-loop system that translates complex biological data into personalized, subscription-based vitamin regimens and dietary guidance. This model effectively shifts the nutritional supplement industry from a generalized, one-size-fits-all approach to a precision-based, evidence-backed health solution, positioning the company as a leader in the burgeoning personalized nutrition market.
How much funding has Baze Labs raised?
Baze Labs has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2019): $6M with participation from Nature's Way
Key Investors in Baze Labs
Nature's Way
A prominent leader in the dietary supplement industry, Nature's Way focuses on high-quality herbal and nutritional products, often acting as a strategic partner for innovative health-tech ventures.
What's next for Baze Labs?
Following this major strategic investment, Baze Labs is well-positioned to scale its operations and deepen its market penetration. The capital will likely be deployed to enhance the company's proprietary diagnostic infrastructure and expand its reach within the competitive health-tech landscape. As the firm transitions from its initial growth phase into a more mature enterprise-level operation, the focus will likely shift toward optimizing supply chain logistics for its subscription supplements and broadening its data analytics capabilities. By maintaining a rigorous commitment to scientific validation, Baze Labs aims to redefine how consumers interact with their own health data, potentially setting a new standard for the future of preventative, personalized nutrition.
See full Baze Labs company page
